ReviewF1000Research2018
Recent advances in understanding rhinovirus immunity.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.PLoS computational biology · 2026Article
- Respiratory Viral Infections and the Tonsillar Transcriptome: An Exploratory Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Molecular Types of Rhinovirus Among Cases of Acute Respiratory Infections in a University Hospital.Journal of medical virology · 2026Article
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.medRxiv : the preprint server for health sciences · 2026Article
- A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.Current pharmaceutical biotechnology · 2026Article
- Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons.Open forum infectious diseases · 2025Article
- Non-T2 asthma.Current opinion in pulmonary medicine · 2025Review
- Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.Molecules (Basel, Switzerland) · 2023Review
- Antiviral Potential of the GenusJournal of ginseng research · 2023Review
- Asthma exacerbations: the Achilles heel of asthma care.Trends in molecular medicine · 2022Review
- Rhinovirus Infection and Virus-Induced Asthma.Viruses · 2022Review
- Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Interactions among common non-SARS-CoV-2 respiratory viruses and influence of the COVID-19 pandemic on their circulation in New York City.Influenza and other respiratory viruses · 2022Article
- Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine.Frontiers in immunology · 2022Review
- Diseases with oral manifestations among adult asthmatics in Finland: a population-based matched cohort study.BMJ open · 2021Article
- Rhinovirus-induced Human Lung Tissue Responses Mimic Chronic Obstructive Pulmonary Disease and Asthma Gene Signatures.American journal of respiratory cell and molecular biology · 2021Article
- Article
- The Molecular Epidemiology and Clinical Phylogenetics of Rhinoviruses Among Paediatric Cases in Sydney, Australia.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Review
- Dual role of the miR-146 family in rhinovirus-induced airway inflammation and allergic asthma exacerbation.Clinical and translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhinoviruses are the most common cause of upper respiratory tract infections. However, they can induce exacerbations of chronic obstructive pulmonary disease and asthma, bronchiolitis in infants, and significant lower respiratory tract infections in children, the immunosuppressed, and the elderly. The large number of rhinovirus strains (currently about 160) and their antigenic diversity are significant obstacles in vaccine development. The phenotype of immune responses induced during rhinovirus infection can affect disease severity. Recognition of rhinovirus and a balance of innate responses are important factors in rhinovirus-induced morbidity. Immune responses to rhinovirus infections in healthy individuals are typically of the T helper type 1 (Th1) phenotype. However, rhinovirus-driven asthma exacerbations are additionally characterised by an amplified Th2 immune response and airway neutrophilia. This commentary focuses on recent advances in understanding immunity toward rhinovirus infection and how innate and adaptive immune responses drive rhinovirus-induced asthma exacerbations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.